|
Model Number BL3170 |
Device Problems
Insufficient Information (3190); Appropriate Term/Code Not Available (3191)
|
Patient Problems
Endophthalmitis (1835); Vitrectomy (2643)
|
Event Date 10/30/2020 |
Event Type
Injury
|
Manufacturer Narrative
|
Additional information regarding the event, the device, and the patient has been requested.The investigation is ongoing.
|
|
Event Description
|
The user facility in france reports 4 cases of endophthalmitis in a month and a half.The 4 cases used 3 different iol brands and different viscoelastic substances.Three of the surgeons used the handpiece, and standard custom packs.Additional information regarding the event, and patient impact has been requested.
|
|
Manufacturer Narrative
|
A bacteriological sampling of all of handpieces was carried out after sterilization as soon as these cases were declared.Everything came back negative except one handpiece (staphylococcus non aureus).The handpiece is in quarantine and will not be put back into circulation.The investigation is ongoing.
|
|
Manufacturer Narrative
|
One stellaris handpiece, serial number (b)(6) was returned in an opened unknown sterilization pouch.The customer was unable to identify which event (see related reports) this handpiece was used in.Close examination of the returned pouch shows that the pouch and presumably the handpiece have been steam sterilized as the indicators on the bag are brown per the exposure key/instructions.Visual inspection and microscopic examination of the handpiece found no damage.The device history record was reviewed with no anomalies noted.A bacteria testing was performed by the customer after steam sterilization, and it was found that the returned device was tested positive for staph aureus bacteria.An endotoxin test was deemed not necessary since the presence of endotoxins cannot pinpoint when it was introduced into the device.Root cause of endophthalmitis could not be determined due to the condition in which the device was returned.The lot history, trend analysis, risk analysis and/or directions for use review were considered acceptable, with the product performing within anticipated rates.No corrective action is necessary.See related reports: 0001920664-2020-00158, 0001920664-2020-00160, 0001920664-2020-00161.
|
|
Manufacturer Narrative
|
Endophthalmitis appeared on monday (b)(6) 2020, 3 days after surgery (i.E.Surgery occurred on 30oct2020).Patient received corrective treatment pos-op day 3 with intravitreal injections of vancomycin + fortum (ceftazidime).This was associated with eye drop antibiotherapy with vancomycin + fortum (ceftazidime) during 5 days.Post-op day 5 the patient received another intravitreal antibiotherapy with vancomycin + fortum(ceftazidime) + celestene (betamethasone).Local corticosteroids were also introduced on day 5 with dexafree(dexamethason) associated with sub conjunctival injections of celestene (betamethasone) every day during one week.As visual acuity did not improve, a vitrectomy was performed.Visual acuity is around 6/10.The lot history, trend analysis, risk analysis and/or directions for use review were considered acceptable, with the product performing within anticipated rates.No corrective action is necessary.See related reports: 0001920664-2020-00158, 0001920664-2020-00160, 0001920664-2020-00161.
|
|
Search Alerts/Recalls
|
|
|